The lung Cediranib price function measurements were not standardized, neither in terms of use of inhaled β2-agonists before the tests nor in terms of time of the day. Patients were instructed in the use of Easyhaler® and they received a questionnaire to be filled in during the study. The instruction of Easyhaler® contained six handling steps: 1. Take off the blue cap   2. Shake the device in an upright position   3. Push the top of the device until you here a click   4. Exhale, put the mouthpiece into your mouth and inhale deeply   5. Repeat steps 2–4 if more than one dose

is prescribed   6. Put the blue cap back on.   The investigator recorded how many times it was necessary to repeat the instructions until the patient could

demonstrate the correct use of the device. The investigator also answered the question of how easy it was to teach the patient in the correct use of Easyhaler®. Visit 2 took place Selleck Ganetespib 1 week later AZD0156 cell line (or within 30 days from visit 1), when handling of Easyhaler® was checked and lung function tests were performed. Lung function tests were performed with standard equipment available at the clinics. Visit 3 took place after 3 months, when handling of Easyhaler® was checked again, lung function tests were performed and the filled-in questionnaire was given back to the investigator. At all three visits, measurements of heart rate and blood pressure were performed as part of an overall safety evaluation. 3.2 Study B This was an open, uncontrolled, non-randomized, multicentre study at ten centres evaluating the efficacy, safety and patient satisfaction of salbutamol Easyhaler® used as needed in children and adolescents with any stage of asthma. Results were obtained at the CDK inhibitor next clinical visit, which usually took place after 3–4 months but always within 1 year from the first visit. Ethics committee approval was obtained via the Central National Procedure. The study protocol was approved under the code 10732-1/2011-EKU (645/PI/11). 3.2.1 Patients Patients should have been 4–17 years of age and using salbutamol pressurized metered dose inhaler (pMDI) with a spacer for temporary relief

of symptoms or prophylactically to avoid exercise- or allergen-induced bronchoconstriction. Children currently using a β2-agonist pMDI attached to a spacer and who may prefer to use a smaller device could also be included. Patients with known hypersensitivity to salbutamol or lactose were excluded. 3.2.2 Medication Patients were asked to inhale one 200 μg dose of salbutamol as needed depending on symptoms but not more than four doses per day. Regular maintenance treatment with salbutamol should be avoided. 3.2.3 Methods There were two clinic visits in the study. First, a screening visit (visit 1) when demographic data and type of inhaler device and spacer used were recorded. Patients were instructed in the use of Easyhaler® (as for Study A).